Cipla Secures Exclusive Rights to Sell Corex, Dolonex, Neksium, Dalacin C Under Pfizer Deal
New Delhi: Cipla Limited has entered into a five-year exclusive supply and marketing agreement with Pfizer Products India Private Limited and Pfizer Limited for marketing and distribution of four brands of Pfizer, namely Corex, Dolonex, Neksium and Dalacin C.
Under the agreement, Cipla now has the sole right to market, distribute, and sell the cough syrups Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium, and the oral antibiotic Dalacin C.
As per the agreement, while Cipla will handle the commercial operations, Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
Cipla stated that the company has an extensive customer understanding, distribution reach, and network. The company believes that the said supply and marketing agreement would ensure a wider reach and depth across India for the said medicines.
Announcing the partnership, Meenakshi Nevatia, Country President, Pfizer India, said, "At Pfizer, expanding the reach of our medicines for patients is paramount, and we are delighted to partner with Cipla to achieve this common mission. With Pfizer’s legacy of breakthroughs, quality and innovation, and Cipla’s extensive distribution reach and network, we believe this partnership will help meet the needs of millions of patients across India effectively. Together, we are committed to advancing healthcare outcomes and enhancing patient lives everywhere.”
Achin Gupta, Global Chief Operating Officer, Cipla Ltd., said, “At Cipla, we believe meaningful partnerships help make strong brands even stronger. This association with Pfizer aligns with our continued focus on building a formidable presence across key therapy areas and enhancing access to high-quality treatments guided by our purpose of ‘Caring for Life’. Our distribution capabilities will support wider reach for such trusted therapies to patients who need them the most.”
Also Read Cipla, Hetero win bid to supply widely prescribed diabetes drug in China
